These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 34932796

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, Tanaka K, Naganuma M, Maeda S.
    Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J, Ji DN, Cai JF, Guan JL, Bao ZJ.
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [Abstract] [Full Text] [Related]

  • 7. Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.
    Zou J, Ji DN, Shen Y, Guan JL, Zheng SB.
    Ann Clin Lab Sci; 2017 Mar; 47(2):171-177. PubMed ID: 28442519
    [Abstract] [Full Text] [Related]

  • 8. Biosimilar infliximab for Behçet's syndrome: a case series.
    Dincses E, Esatoglu SN, Ozguler Y, Uygunoglu U, Hamuryudan V, Seyahi E, Melikoglu M, Fresko I, Ucar D, Ozyazgan Y, Kutlubay Z, Mat MC, Yurdakul S, Siva A, Hatemi G.
    Clin Exp Rheumatol; 2019 Mar; 37 Suppl 121(6):111-115. PubMed ID: 31856937
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, Tanida S, Kataoka H, Sasaki M.
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.
    Guzelant G, Ucar D, Esatoglu SN, Hatemi G, Ozyazgan Y, Yurdakul S, Seyahi E, Yazici H, Hamuryudan V.
    Clin Exp Rheumatol; 2017 Jul; 35 Suppl 108(6):86-89. PubMed ID: 29148418
    [Abstract] [Full Text] [Related]

  • 15. Infliximab therapy in Behçet's uveitis.
    Alizadegan F, Yalcinbayir O, Ucan Gunduz G, Pehlivan Y.
    J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
    [Abstract] [Full Text] [Related]

  • 16. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
    Horiguchi N, Kamoi K, Horie S, Iwasaki Y, Kurozumi-Karube H, Takase H, Ohno-Matsui K.
    Sci Rep; 2020 Dec 17; 10(1):22227. PubMed ID: 33335139
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.